Accenture invests in Turbine to advance AI-powered drug discovery


Accenture (NYSE: ACN) has announced a strategic investment through Accenture Ventures into Turbine, a pioneering predictive simulation company. This investment aims to enhance Turbine’s capabilities in delivering profound biological insights to global biopharma companies, thereby accelerating key drug development processes.

Revolutionizing Drug Discovery with AI

Turbine’s proprietary technology, the Simulated Cell platform, harnesses machine learning to model molecular interactions and cell decision-making processes. This advanced platform allows for conducting virtual experiments on a scale that is impractical in the physical world, uncovering critical mechanisms driving diseases and therapy responses. Tom Lounibos, global lead of Accenture Ventures, emphasized the impact of digital and AI capabilities in biopharma: “The future of drug discovery will increasingly rely on AI, and Turbine’s platform is proving essential in unlocking valuable biological insights.”

See also  Accenture acquires martech consultancy Lumery to enhance customer experience capabilities

The investment will further Turbine’s research and development efforts, particularly in expanding the application of its platform to identify viable drug targets, optimize patient selection for therapies, and determine effective combination treatments. These initiatives are vital in revealing hidden treatment options and avoiding potential clinical trial failures.

Enhancing Global Biopharma Capabilities

Petra Jantzer, Ph.D., senior managing director and global lead of the Accenture Life Sciences business, highlighted the strategic value of the investment: “Turbine’s Simulated Cell platform is a crucial tool for biopharma companies to gain insights into complex biological systems, which is instrumental in developing targeted treatments and improving patient care.”

Turbine’s collaboration with Accenture is set to expand its market reach and enhance its simulation platform, making significant strides in the biopharma industry. Szabolcs Nagy, co-founder and CEO of Turbine, remarked on the synergy: “By leveraging Accenture’s expertise, we aim to augment our platform, ensuring that each new experiment conducted is optimally informative and impactful.”

See also  Enveda Biosciences secures $55m to advance AI-driven drug discovery

Project Spotlight: Fostering Innovation Through Strategic Investments

Turbine joins Accenture Ventures’ Project Spotlight, an initiative that connects disruptive technology startups with Accenture’s vast expertise and client network. This program is designed to enhance startups’ market presence and accelerate the realization of their technological innovations. Project Spotlight includes other notable digital simulation companies like QuantHealth, Virtonomy, and Ocean Genomics, all contributing to the diversification and advancement of enterprise technologies.

See also  Accenture bolsters digital capabilities with OPENSTREAM acquisition

While the specific terms of the investment remain undisclosed, this move is indicative of Accenture’s commitment to integrating cutting-edge technologies like AI into drug discovery and development, reaffirming its role as a catalyst in the transformation of the biopharma sector.

Accenture’s investment in Turbine is a strategic move that reflects the growing importance of AI and machine learning in the pharmaceutical industry. By focusing on simulation and predictive technologies, Accenture is not only fostering innovation but also potentially altering the landscape of drug discovery and patient treatment strategies. This partnership is expected to drive forward the capabilities of AI in medicine, offering promising new avenues for tackling complex diseases with precision and efficiency.

Share This